ArticleNature biotechnology2011
Comprehensive analysis of kinase inhibitor selectivity.
Article in Nature biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,108 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,108 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis.Frontiers in oncology · 2025Pooled it
- Deep Learning Protocols for Predicting Drug Mechanism of Action and Drug-Target Interactions.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Citron Kinase, a mitotic kinase with increasing significance in cancer.Cell cycle (Georgetown, Tex.) · 2026Review
- MLDTA an Ensemble-Driven Multimodal Model with Dynamic Fusion for Drug-Target Affinity Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- qcGEM: A Graph-Based Molecular Representation With Quantum Chemistry Awareness.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- The rise of agentic AI in drug discovery from static tools to autonomous virtual scientists.npj drug discovery · 2026Review
- CUE: A Chemical Uncertainty-Aware Embedding Framework for Multimodal Drug Selectivity Prediction.Journal of chemical information and modeling · 2026Article
- Benchmarking Boltz-2 for relative kinase-inhibitor interaction patterns across conformational states and resistance mutations.npj drug discovery · 2026Article
- Unifying AI-assisted scientific discovery around exploration, hypothesis generation, and testing.Patterns (New York, N.Y.) · 2026Review
- Article
- VCCV: conservative transcriptomic corroboration for measurement prioritization of computational drug-target hypotheses.Bioinformatics (Oxford, England) · 2026Article
- Chemical language models for early-stage drug discovery: applications, pitfalls, and future directions.Journal of computer-aided molecular design · 2026Review
- Modulating pseudokinase conformation from the ATP-binding site.Structure (London, England : 1993) · 2026Article
- KAN-GIN: Adaptive Nonlinear Molecular Representation Learning for Drug-Target Affinity Prediction.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Confidence-Gated Triage: Coupling Drug-Target Affinity and ADME-T Predictions to Prioritise Compounds for Docking.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib Leads to Potent and Selective Quinoline-Based HIPK4 Inhibitor AZ137.Journal of medicinal chemistry · 2026Article
- IIC-DTI: A Contrastive Learning Enhanced Inter-Intra Molecular Fusing Framework for Drug-Target Interaction Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- GSF-DTA: An Innovative Graph-Sequence Fusion Framework for Drug-Target Affinity Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- A Scalable and Robust Ensemble Deep Learning Method for Predicting Drug-Target Interactions.Interdisciplinary sciences, computational life sciences · 2026Article
1,048 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome. Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend. The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compounds tested. Analysis of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily. The data set suggests compounds to use as tools to study kinases for which no dedicated inhibitors exist. It also provides a foundation for further exploring kinase inhibitor biology and toxicity, as well as for studying the structural basis of the observed interaction patterns. Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.
Indexed as
Identifiers
22037378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.